
TUMOUR GROWTH PARAMETER ESTIMATION FROM DOUBLING TIMES

Mohammed Arshad Ali*
Ahmed Waheedullah**

Abstract

Awareness of tumour growth characteristics is important in treatment of deadly disease Cancer. Experiments take lengthy time to explore the characteristics and availability of required sample size is another drawback in making conclusions about tumour growth characteristics. Mathematical modeling and statistical theory facilitates in predicting results without conducting experiments practically and making inferences about tumour growth parameters from sample characteristics. In this paper, the proliferation rates and interval estimates of proliferation rates with different confidence levels of various human cancer tumours were estimated with the help of tumour growth equation and sampling theory using doubling times from experimental data.

Keywords:

Proliferation rate;
Tumour doubling time;
Tumour growth parameter;
Cell proliferation;
Tumour spheroid growth.

Copyright © 2017 International Journals of Multidisciplinary Research Academy. All rights reserved.

Author correspondence:

Mohammed Arshad Ali,
Associate Professor, Deccan school of Management, Hyderabad, India.

1. Introduction

Cancer is a deadly disease with a symptom of abnormal and uncontrolled growth of tissue at any part of the human body. The characteristics of tumours such as location, stage of the tumour, size and nature of the tumour cells plays very important role in treatment of Cancer. If the growth of the tumour is very rapid, it could be dangerous to the patient. If tumour cells reach another place through blood vessels, it will initiate a new growth at different place of the body in addition to the already grown tumour at previous site. In the fast growing tumours, delay in treatment may lead to further tumour growth and complications in the patients. The early treatment may reduce the chances of metastasis and increase the chances of cure and survival of the patient. The tumour doubling time is one such character which indicates time taken by the tumour to double its size or volume will be helpful in treating cancer. Doubling times varies from tissue to tissue depending upon the nature of the tissue cells. In Mathematical terminology, another parameter, the rate at which tumor cells grow or multiply themselves is known as proliferation rates can be estimated from tumour doubling times by considering the tumour in a spherical shape. With the information of a specific character like proliferation rate of tumor cells belonging to a particular type of tumour, the task will be very easy in dealing with cancer related research work and also in treatment of cancer by any method of treatment. The proliferation rates of the different tumour cells, the range values of the tumour proliferation rates and confidence intervals for population proliferation rates with 0.90, 0.95 and 0.99 confidence levels were

*Associate Professor, Deccan school of Management, Hyderabad, India.

** Retired Professor, MJ College of Engineering & Technology, Hyderabad, India.

estimated from the tumor doubling times with the help of tumour growth equation and statistical theory from the experimental data.

2. Literature Review

Cancer research related to tumour spheroids and mathematical modeling of tumor growth dates back to late 1960's. Growth of multi cell tumours were examined by Burton A.C. (1966), Judah Folkman and Mark Hochberg (1973), H.P. Greenspan (1973), R.M. Sutherland (1974), etc. Mathematical models have been developed by considering the behaviour of multi cell tumour spheroids *in vitro* experiments using diffusion theory. Burton A.C (1966) developed a model using diffusion theory and showed that the growth of solid tumours is not exponential but it follows Gompertzian relation. The doubling times of various histological types of human tumours were studied by Malaise et al, (1973) [7], experimental potential doubling times of human tumours were obtained by E.H. Cooper, A.J. Bedford and T.E. Kenny [4], the experimental doubling times of primary and metastatic human tumours were calculated by Renato Baserga [8], range of doubling times of were studied by Esmael Mehrara et. al [3] and doubling times of cell lines from various panels based on clinical research weretaken from the website of National cancer institute of United States of America[9].

3. Methodology

By assuming only proliferating cells contribute to the growth of the tumour spheroid and considering a total N number of cells with volume v of each cell in the tumor spheroid containing only N_p proliferating cells with proliferation rate s , the increase in total number of cells N in time Δt is taken as ΔN . The ΔN can be calculated as the product of number of proliferating cells, proliferation rate and time.

$$\Delta N = N_p \times s \times \Delta t, \quad \Delta N = (s \cdot \Delta t) N_p.$$

If we take $\Delta t \rightarrow 0$, $\frac{\Delta N}{\Delta t} = s \cdot N_p$ (i.e) $\frac{dN}{dt} = s \cdot N_p$ (sis the proliferation rate which can be taken as rate constant of cell production). In place of individual cells, if we consider volume as whole, it will become $\frac{dV}{dt} = s \cdot V_p$ (where $V_p = v \cdot N_p$). If all the cells are proliferating or when the tumour is small, we consider $N = N_p$ and $V = V_p$. By considering the initial radius of tumour spheroid as R_0 , $\frac{dV}{dt} = s \frac{4\pi}{3} R_0^3$. This will lead to the differential equation $\frac{dR_0}{dt} = \frac{s}{3} R_0$. This is a first order linear differential equation whose solution will be $R_0 = k \cdot e^{\frac{st}{3}}$. By taking initial conditions, at time $t = 0$, $R_0(0) = R_0$, gives $k = R_0(0)$. The solution can be taken as $R_0(t) = R_0(0) e^{\frac{st}{3}}$. Since the volume ($V = \frac{4\pi}{3} R_0^3$) of the tumour spheroid is directly proportional to the radius, we get $V(t) = V(0) e^{st}$. Let us consider the time taken by the tumour to double its volume is t_d . Then the equation $V(t) = V(0) e^{st}$ will become $2V(t) = V(0) e^{st_d}$. Taking natural logarithms on both sides and solving, we get $s = \frac{\ln 2}{t_d}$. The advantage of the mathematical modeling is to predict the result with out going for the experimental work. The proliferation rates can be calculated from available tumour doubling times and other parameters depending on the proliferation rate can be estimated with out waiting for a lengthy time.

In the experiments, the time taken for the cells to double their size assuming no cell loss is considered as potential doubling time t_{pot} and if there is cell loss, the time taken to double their size is considered as doubling time t_d . In this study, the time taken to double the size of the tumor with or with out cell loss is considered as t_d . In some experiments, instead of giving single value to doubling time, a range of values is used. In such cases, interval estimate of the proliferation rate is calculated. Since availability of a particular type of tumour cell is a constraint to the investigator, the numbers of tumours are less than 30, it is considered as small sample with size $n < 30$. In sampling theory, by considering the characteristics of the sample, we can make inferences about population parameter. The experimental results are used to estimate the unknown parameter (mean proliferation rate) of the tumour population in the form of interval estimate. While finding interval estimates, the confidence levels of 90%, 95% and 99% are considered. With respect to 90% confidence level, we can say the interval estimate will include the true population parameter 90% of the time and 10% ($\alpha = 0.10$) of the time it may not be. In these cases, α is considered as Significance level. The same assumption applies to 95% and 99% confidence interval estimates also with ($\alpha = 0.05$ & 0.01) respectively. Since $n < 30$, student's t distribution is used with the formula [Mean of the sample $\pm (t) \cdot (\text{standard error of mean})$] with degrees of freedom ($n - 1$). To visualize and to have clear nature of the tumour cells of similar type, scatter diagrams are obtained with the help of MATLAB.

4. Results and Conclusions

1. The experimental data related to doubling times of various histological types of human tumours by Malaise et al, (1973) published in European journal of cancer, vol 9, 305-312 with reference from the book “An introduction to radiobiology” by A.H.W. Nias is taken for estimating of their corresponding proliferation rates and are shown in the table 1.

2. The proliferation rates of human tumours by using experimental potential doubling time data of human tumours by E.H. Cooper, A.J. Bedford and T.E. Kenny in ‘cell death in normal and malignant tissues’ from “Advances in cancer research; volume 21” are shown in the table 2.

3. The experimental doubling times of primary and metastatic human tumours from the book “The biology of cell reproduction” by Renato Baserga are used to calculate proliferation rates which are shown in the table 3.

4. Clinical data related to tumour doubling times from Esmael Mehrara et. al which contains range of values for doubling times and some similar type of tumours with different researchers is taken to calculate proliferation rate range in the table 4.

5. Much more detailed information on doubling times of cell lines from various panels based on extensive research work is taken from website of National cancer institute of United States of America, to calculate proliferation rates and shown in the tables 5&6.

6. For the nine panels of tumours with 61 different cells mentioned in the table 5 and table 6, Interval estimates of population parameter (mean proliferation rate of the panel) is obtained by calculating sample mean, sample standard deviation and standard error of the mean with confidence levels 0.90, 0.95 & 0.99 respectively which are shown in the table 7.

7. For the purpose of comparison between different panels and to visualize variations within the panels, scatter diagrams of 9 panels were obtained with the help of MATLAB which is shown in the figure 8.

8. From the data in the tables 4, 5, 6 and 7 it was clear that even for the tumours of similar type, the doubling times are not same. But they may lie between certain limits. The same observation can be seen even for proliferation rates as they have been calculated from tumour doubling times. The results can be clearly seen in the scatter diagrams in the figure 8 which are scattered between certain limits without coincidence.

9. The advantage of mathematical modeling is to predict the result without going for the experimental work. If the proliferation rates are known, the rate in change of volume over a period of time can be estimated with the initial volume of the tumour.

Histological type	Doubling time (days)	<i>Proliferation rate (s)</i>
Embryonal tumour	27	0.02567
Malignant lymphoma	29	0.02390
Sarcoma	41	0.01690
Squamous cell carcinoma	58	0.01195
Adenocarcinoma	83	0.00835

Table1. Table showing estimated proliferating rates of various histological types of human tumours.

Lymphomas	Number of tumours measured	Potential doubling Times (days)	<i>Proliferation rate (s)</i>
Hodking's disease	10	1.8	0.38508
Recticulum cell sarcoma	13	1.6	0.43322
Lymphatic lymphoma	12	1.6	0.43322
Histiocytic - lymphocytic	5	4.0	0.17329
Burkitt tumour (1)	26	1.4	0.49510
Burkitt tumour (2)	23	1.9	0.36481
Carcinoma of bladder	32	15.0	0.04621
Carcinoma of colon	31	10.4	0.06665
Carcinoma of the breast	38	43	0.01612

Table2. Table showing estimated proliferating rates of human tumours corresponding to their potential doubling times

Type of Tumour	Mean volume doubling Time in days	<i>Proliferation rate (s)</i>
Primary tumours		
Squamous cell carcinoma of the lung	84	0.00825
Adenocarcinoma of colon and rectum	632	0.00110
Carcinoma of the breast	96	0.00722
Sarcoma of bone	63	0.01100
Metastases in the lung, from		
Adenocarcinoma of colon and rectum	95	0.00730
Carcinoma of the breast	73	0.00950
Ewing's sarcoma	17	0.04077
Sarcoma of bone	30	0.02310
Melanoma	53	0.01308
Lymphoma	27	0.02567

Table3. Table showing estimated proliferation rates of primary and secondary tumours calculated from their mean volume doubling time.

S.No	Reference	Tumour	Sample Size (<i>n</i>)	Doubling time range (<i>t_d</i>)	Proliferation Rate range (<i>s</i>)
1	(Nishida, Kaneko et al. 1999)	Pancreatic carcinoma	12	18-232	0.0030 - 0.0385
2	(Furukawa, Iwata et al. 2001)	Pancreatic carcinoma	9	64-255	0.0027 - 0.0108
3	(Wang, Some et al. 2000)	Adenocarcinoma (lung)	8	72-131	0.0053 - 0.0096
4	(Winer-Muram, Jennigs et al. 2002)	Adenocarcinoma (lung)	15	(-1350)-964	-0.0005 - 0.0007
5	(Winer-Muram, Jennigs et al. 2002)	Bronchioalveolar(lung)	9	36-1092	0.0006 - 0.0193
6	(Winer-Muram, Jennigs et al. 2002)	Squamous cell lung carcinoma	16	(-1214)-225	-0.0006 - 0.0031
7	(Winer-Muram, Jennigs et al. 2002)	Non small cell lung carcinoma	6	48-698	0.0100 - 0.0144
8	(EI Sharouni, Kal et al. 2003)	Non small cell lung cancer	18	8-171	0.0040 - 0.0866
9	(Wang, Sone et al. 2000)	Small cell lung cancer	4	54-132	0.0052 - 0.0128
10	(Blomqvist, Wiklund et al. 1993)	Sarcoma(lungmetastases)	21	7-1172	0.0006 - 0.0990
11	(Nakajima, Moriguchi et al. 2002)	Hepatocellular carcinoma (well differentiated)	19	38-274	0.0025 - 0.0182
12	(Saito, Matsuzaki et al. 1998)	Hepatocellular carcinoma (well differentiated)	15	76-720	0.0010 - 0.0091
13	(Nakajima, Moriguchi et al. 2002)	Hepatocellular carcinoma (moderately differentiated)	9	17-91	0.0076 - 0.0408
14	(Saito, Matsuzaki et al. 1998)	Hepatocellular carcinoma (moderately differentiated)	5	94-380	0.0018 - 0.0074
15	(Nakajima, Moriguchi et al. 2002)	Hepatocellular carcinoma (poorly differentiated)	5	20-78	0.0089 - 0.0347

Table4. Table showing number of tumours,doubling time range and their proliferation range including references

S.No	Cell Line Name	Panel Name	Doubling time	Proliferation rate (s)
1	CCRF-CEM	Leukemia	26.7	0.02596
2	HL-60(TB)	Leukemia	28.6	0.02424
3	K-562	Leukemia	19.6	0.03536
4	MOLT-4	Leukemia	27.9	0.02484
5	RPMI-8228	Leukemia	33.5	0.02069
6	SR	Leukemia	28.7	0.02415
7	A549/ATCC	Non-Small Cell Lung	22.9	0.03027
8	EKVX	Non-Small Cell Lung	43.6	0.01590
9	HOP-62	Non-Small Cell Lung	39	0.01777
10	HOP-92	Non-Small Cell Lung	79.5	0.00872
11	NCI-H226	Non-Small Cell Lung	61	0.01136
12	NCI-H23	Non-Small Cell Lung	33.4	0.02075
13	NCI-H322M	Non-Small Cell Lung	35.3	0.01964
14	NCI-460	Non-Small Cell Lung	17.8	0.03894
15	NCI-H522	Non-Small Cell Lung	38.2	0.01814
16	COLO 205	Colon	23.8	0.02912
17	HCC-2998	Colon	31.5	0.02200
18	HCT-116	Colon	17.4	0.03983
19	HCT-15	Colon	20.6	0.03365
20	HT29	Colon	19.5	0.03555
21	KM12	Colon	23.7	0.02925
22	SW-620	Colon	20.4	0.03398
23	SF-268	CNS	33.1	0.02094
24	SF-295	CNS	29.5	0.02350
25	SF-539	CNS	35.4	0.01958
26	SNB-19	CNS	34.6	0.02003
27	SNB-75	CNS	62.8	0.01104
28	U251	CNS	23.8	0.02912
29	LOXIMVI	Melanoma	20.5	0.03381
30	MALME-3M	Melanoma	46.2	0.01500
31	M14	Melanoma	26.3	0.02636

Table5. Table showing cell line name, panel name with their doubling time and estimated proliferation rates.

S.No	Cell Line Name	Panel Name	Doubling time	Proliferation rate (s)
32	MDA-MB-435	Melanoma	25.8	0.02687
33	SK-MEL-2	Melanoma	45.5	0.01523
34	SK-MEL-28	Melanoma	35.1	0.01975
35	SK-MEL-5	Melanoma	25.2	0.02751
36	UACC-257	Melanoma	38.5	0.01800
37	UACC-62	Melanoma	31.3	0.02215
38	IGR-OVI	Ovarian	31	0.02236
39	OVCAR-3	Ovarian	34.7	0.01998
40	OVCAR-4	Ovarian	41.4	0.01674
41	OVCAR-5	Ovarian	48.8	0.01420
42	OVCAR-8	Ovarian	26.1	0.02656
43	NCI/ADR-RES	Ovarian	34	0.02039
44	SK-OV-3	Ovarian	48.7	0.01423
45	786-0	Renal	22.4	0.03094
46	A498	Renal	66.8	0.01038
47	ACHN	Renal	27.5	0.02521
48	CAKI-1	Renal	39	0.01777
49	RXF 393	Renal	62.9	0.01102
50	SN12C	Renal	29.5	0.02350
51	TK-10	Renal	51.3	0.01351
52	UO-31	Renal	41.7	0.01662
53	PC-3	Prostate	27.1	0.02558
54	DU-145	Prostate	32.3	0.02146
55	MCF7	Breast	25.4	0.02729
56	MDA-MB-231/ATCC	Breast	41.9	0.01654
57	MDA-MB-468	Breast	62	0.01118
58	HS 578T	Breast	53.8	0.01288
59	MDA-N	Breast	22.5	0.03081
60	BT-549	Breast	53.9	0.01286
61	T-47D	Breast	45.5	0.01528

Tabl6. Table showing cell line name, panel name with their doubling time and estimated proliferation rates

S. No	Panel Name	Average (\bar{s})	Standard deviation (σ_s)	90% Confidence Interval $(\alpha = 0.10)$	95% Confidence Interval $(\alpha = 0.05)$	99% Confidence Interval $(\alpha = 0.01)$
1	Leukemia	0.0259	0.0050	0.0218 -- 0.0300	0.0207 -- 0.0311	0.0177 – 0.0341
2	Non-Small Cell Lung	0.0206	0.0084	0.0154 -- 0.0258	0.0141 – 0.0271	0.0140 – 0.0272
3	Colon	0.0319	0.0057	0.0277 – 0.0361	0.0266 – 0.0372	0.0234 – 0.0399
4	CNS	0.0207	0.0059	0.0158 – 0.0256	0.0145 – 0.0269	0.0110 – 0.0304
5	Melanoma	0.0227	0.0064	0.0187 – 0.0267	0.0178 – 0.0276	0.0156 – 0.0298
6	Ovarian	0.0192	0.0045	0.0159 – 0.0225	0.0150 – 0.0234	0.0129 – 0.0255
7	Renal	0.0186	0.0073	0.0137 – 0.0235	0.0125 – 0.0247	0.0096 – 0.0276
8	Prostate	0.0235	0.0029	0.0106 – 0.0364	0.0000 – 0.0756	0.0000 – 0.2835
9	Breast	0.0181	0.0077	0.0124 – 0.0238	0.0110 – 0.0252	0.0073 – 0.0289

Table7. Table showing average, standard deviation of proliferation rates with their confidence intervals




Figure8. Scatter diagrams showing proliferation rates of cell lines from different panels

4. References

- [1] A.C. Burton, Rate of growth of solid tumours as a problem of diffusion, *Growth***30**(1966), pp 157-176.
- [2] Folkman J, and M. Hochberg, (1973), Self regulation of growth in three dimensions. *J. Exp .Med*138: pp 745-753
- [3] EsmaelMehrraet al, Specific Growth Rate Verses Doubling Time for Quantitative Characterization Of Tumor growth rate “*Advances in cancer research*”; 2007;67: pp 3970-3975
- [4] E.H. Cooper, A.J. Bedford and T.E. Kenny in ‘cell death in normal and malignant tissues’ “*Advances in cancer research*; volume 21”1975; pp 21:59-120
- [5] H.P. Greenspan, Models for the growth of a solid tumor by diffusion, *Stud.Appl.Math.*52 (1972),pp 317-340.
- [6] H.P. Greenspan, On the growth and stability of cell cultures and solid tumors, *J. Theor. Biol.*56 (1976), pp 229-242
- [7] A.H.W. Nias, An Introduction to Radiobiology, 2nd Edition,John Wiley & Sons (1998)
- [8] Renato Baserga, The Biology of Cell Reproduction, Harvard University Press, (1985)
- [9] https://ntp.cancer.gov/discovery_development/nci-60/cell_list.htm

Note: Above article is a part of the research work carried out in Ph.Dcurriculum under Osmania University in Department of Mathematics with topic “Theoretical Study of Problems in Life sciences and Medicine”.